• Gemini completes enrollment in phase 2a trial of dry AMD therapy

    One year ago - By Healio

    Gemini Therapeutics completed enrollment in a phase 2a study investigating safety and tolerability of GEM103 in dry age-related macular degeneration, according to a press release.
    ReGAtta is an ongoing, multicenter, open-label, multiple ascending dose study of a recombinant form of the human complement factor H protein in patients with dry AMD and CFH loss-of-function gene variants, the release said.
    “Our strategy is to provide an intravitreal recombinant human factor H in patients with gene variants resulting in loss of function of their own CFH,” Marc E. Uknis, MD, FACS,
    Read more ...